LIVE MARKET TRACKER :   BSE SENSEX   31599.76      |    NSE NIFTY 9871.50    
GLOBAL MARKETS :  NASDAQ 6370.5898   -0.8765%    |    FSI London 7302.97   +0.02%    |    NIKKEI Japan 20330.19   -0.33%
  USD GBP EUR CAD AUD INR
USD - 0.7444 0.8485 1.2377 1.2675 65.6000
GBP 1.3434 - 1.1397 1.6627 1.7023 88.1346
EUR 1.1789 0.8777 - 1.4591 1.4941 77.3161
CAD 0.8081 0.6022 0.6855 - 1.0245 53.0080
AUD 0.7892 0.5875 0.6695 0.9767 - 51.7590
INR 0.0153 0.0114 0.0129 0.0189 0.0194 -
Indian-Commodity  :  IPO  :  Sakar Healthcare to hit capital markets to raise Rs 14.81 crore

Sakar Healthcare to hit capital markets to raise Rs 14.81 crore (30-Sep-2016)

Sakar Healthcare is coming out with a 100% book building; initial public offering (IPO) of 29,61,000 equity shares of Rs 10 each in a price band Rs 42-50 per equity share. The issue will open on September 30, 2016 and will close on October 05, 2016. The shares will be listed on NSE Emerge platform.

The company will use the issue proceeds for setting up a new Lyophilization facility to manufacture Lyophilized Products (Injectable) in existing unit at Changodar, Ahmedabad, Gujrat, obtaining registration of European Union GMP, registering new products, meeting working capital requirement and meeting general corporate purposes.

The book running lead manager to the issue is Pantomath Capital Advisors, while the compliance officer for the issue is Pratixa Seju.

The company is an Indian pharmaceutical company engaged in the manufacturing and marketing of its own pharmaceutical formulations for domestic and international markets. Its Product domestic sales are generally exported by third party. It also undertakes contract manufacturing of formulations for pharmaceutical companies based in India.


Top News Today
Jaiprakash Associates gets nod to raise up to Rs 2,000 crore
(26-Sep-2017)

Jaiprakash Associates gets nod to raise up to Rs 2,000 croreJaiprakash Associates has received its shareholders' approval to raise up to Rs 2,000 crore through sale of securities. The special resolution was approved by the shareholders at the company's annual general......click on news to read complete article.

Panacea Biotec planning to raise Rs 250 crore
(26-Sep-2017)

Panacea Biotec planning to raise Rs 250 crorePanacea Biotec is planning to raise Rs 250 crore by way of issue of equity shares and/or other securities. In this regards, the company is conducting Postal Ballot for obtaining approval of members for......click on news to read complete article.

Novartis India gets nod for Rs 231.15 crore buyback plan
(26-Sep-2017)

Novartis India gets nod for Rs 231.15 crore buyback planNovartis India has received an approval for buyback of up to 34.5 lakh shares, accounting for about 12.26% of the existing paid up capital of the company, for up to Rs 231.15 crore. The company's board......click on news to read complete article.

International Stock News
Asian markets trade mostly lower in early deals on Tuesday
(26-Sep-2017)

Asian markets trade mostly lower in early deals on TuesdayMost of the Asian equity benchmarks are trading down in the early deals on Tuesday, following declines on Wall Street overnight, as the war of words between North Korea and the US escalated. Meanwhile,......click on news to read complete article.

US markets closed lower on North Korea's threat
(26-Sep-2017)

US markets closed lower on North KoreaThe US markets closed lower on Monday, on the back of a fresh flare up in tensions between the US and North Korea and a sharp decline in technology shares. North Korean foreign minister Ri Yong Ho, speaking......click on news to read complete article.

Asian markets trade mostly lower in early deals on Monday
(25-Sep-2017)

Asian markets trade mostly lower in early deals on MondayMost of the Asian equity benchmarks are trading down in the early deals on Monday, following the lackluster cues from Wall Street and concerns about China's economy. Investors digested election results......click on news to read complete article.

 

     
  
Recent IPO News
 
EquityInvestmentCompany ReportsIPO
Disclaimer
By clicking on this page you accept all the terms and conditions framed by us. News made available here are for informational purpose only. While utmost care has been taken in providing the same. We claim no responsibility for its accuracy. Readers of this blog who make their decision based on the information posted here are solely responsible for their actions.